ARTV Form 4: Executive RSU Tax Withholding Reduces Horan Holdings
Artiva Biotherapeutics insider Christopher Horan reported two dispositions of common stock tied to restricted stock unit vesting and tax withholding.
Rhea-AI Filing Summary
Artiva Biotherapeutics insider Christopher Horan reported two dispositions of common stock tied to restricted stock unit vesting and tax withholding. On 05/15/2025 he had 1,341 shares withheld at an effective price of $2.13, reducing his direct ownership to 83,659 shares. On 08/15/2025 he had 3,577 shares withheld at $2.75, reducing his direct ownership to 80,082 shares. The filing identifies Horan as Chief Tech Operations Officer and was signed by an attorney-in-fact on 08/18/2025. The form states these share reductions "represent shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards," indicating these were not open-market sales but withholding transactions connected to equity compensation.
Positive
- Disclosure of tax-withholding on RSU vesting demonstrates compliance with Section 16 reporting requirements
- Transactions are administrative (withholding) rather than open-market sales, reducing likelihood of signaling liquidity-driven selling
Negative
- None.
Insights
TL;DR: Routine tax-withholding on RSU vesting, shows governance-compliant disclosure but no change to control.
The Form 4 discloses withholding of vested restricted stock units to satisfy income taxes, a standard practice that reduces reported beneficial ownership without indicating a voluntary divestiture. This preserves executive compensation mechanics while maintaining transparency. The reductions do not suggest a change in voting control or a disposition for liquidity. Documentation signed by an attorney-in-fact is common for administrative filings.
TL;DR: Non-market withholding lowers share count modestly; no evidence of opportunistic selling or material ownership shift.
The transactions are labeled as tax-withholding from RSU vesting, with 1,341 shares withheld at $2.13 and 3,577 shares withheld at $2.75, bringing direct holdings to 80,082 shares. For a public company, these amounts are minor relative to typical outstanding share counts and do not meet materiality thresholds for investor-impactful events. The reporting is consistent with Section 16 requirements.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise Price or Tax Liability | Common Stock | 3,577 | $2.75 | $10K |
| Exercise Price or Tax Liability | Common Stock | 1,341 | $2.13 | $3K |
Footnotes (1)
- F1. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.
FAQ
What did Christopher Horan report on the Form 4 for ARTV?
Do the reported transactions represent open-market sales of ARTV stock?
What is Christopher Horan's role at Artiva Biotherapeutics as listed on the Form 4?
Who signed the Form 4 submission for these transactions?
AI-generated analysis. How Rhea-AI works. Not financial advice.